Safety and efficacy of abrafenib plus trametinib in patients with BRAF V600-mutant unresectable or metastatic melanoma as part of the Managed Access Program (MAP) in Italy
Latest Information Update: 19 Nov 2021
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Acronyms DESCRIBE Italy
- Sponsors Novartis
- 19 Nov 2021 New trial record
- 10 Nov 2021 Results published in the Targeted Oncology